Compare Novartis AG (NVS) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs State Street Technology Select Sector SPDR ETF — how do they compare? Novartis AG trades at $139.7 (market cap $262.28B), while State Street Technology Select Sector SPDR ETF trades at $187.24. The key difference: Novartis AG pays a 3.45% dividend while State Street Technology Select Sector SPDR ETF pays none, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | XLK | |
|---|---|---|
Market Cap | $262.28B | — |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $198.21 |
52-Week Low | $121.80 | $127.49 |
Enterprise Value | $303.60B | — |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
XLK trades at $187.87, up 0.3% today, with a bullish technical signal from moving averages and support at $185. The ETF holds a concentrated mega-cap tech strategy with a low 0.08% expense ratio, though key financial ratios are unavailable. Recent news highlights sector inflows and AI-driven software shifts.
Outlook is supported by tech sector momentum and AI adoption, but risks include high concentration in top holdings and valuation sensitivity. Analysts favor XLK for its cost efficiency and exposure to AI growth, yet investors face volatility from economic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
